<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="152987">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01108393</url>
  </required_header>
  <id_info>
    <org_study_id>CL2-20098-072</org_study_id>
    <secondary_id>2009-016713-20</secondary_id>
    <nct_id>NCT01108393</nct_id>
  </id_info>
  <brief_title>Efficacy of Agomelatine in Patients With Obsessive-Compulsive Disorder</brief_title>
  <official_title>Efficacy of Agomelatine 25mg/Day (With Possible Increase to 50mg/Day After 8 Weeks of Treatment) Given Orally During 16 Weeks in Patients With Obsessive-Compulsive Disorder. A Randomised, Double-blind, Placebo-controlled, Parallel Groups, International Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Servier</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Servier</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will evaluate the efficacy of agomelatine compared to placebo on the reduction of
      Obsessive and Compulsive symptoms after 16 weeks of treatment.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2010</start_date>
  <completion_date type="Actual">April 2013</completion_date>
  <primary_completion_date type="Actual">August 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Y-BOCS total score</measure>
    <time_frame>16 weeks</time_frame>
    <description>Yale-Brown Obsessive Compulsive scale (Y-BOCS) total score. This scale measures the severity of obsessive and compulsive symptoms from baseline to W16.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>NIMH-OC score</measure>
    <time_frame>16 weeks</time_frame>
    <description>National Institute for Mental Health- Obsessive Compulsive scale (NIMH-OC) Total Score. This scale measures the severity of obsessive and compulsive symptoms from baseline to week 16.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MADRS total score</measure>
    <time_frame>16 weeks</time_frame>
    <description>Montgomery and Asberg Depression rating scale (MADRS) Total score. This scale measures the severity of depressive symptoms from baseline to week 16.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">74</enrollment>
  <condition>Obsessive Compulsive Disorder</condition>
  <arm_group>
    <arm_group_label>Agomelatine A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Agomelatine A</intervention_name>
    <description>Agomelatine 25 mg film-coated tablet
Agomelatine 2x25mg film-coated tablet</description>
    <arm_group_label>Agomelatine A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Obsessive Compulsive Disorder (OCD) according to Diagnostic and Statistical Manual,
             Fourth Edition, Text Revision (DSM-IV-TR),

          -  Y-BOCS total score â‰¥ 20,

          -  duration of OCD symptoms of at least one year.

        Exclusion Criteria:

          -  Bipolar disorder, Schizophrenic or Psychotic Disorder

          -  Severe or uncontrolled organic diseases

          -  Neurological disorder

          -  Women of childbearing potential who are not using effective contraception
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joseph Zohar, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Psychiatry Chaim Sheba Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Psychiatry Chaim Sheba Medical Center</name>
      <address>
        <city>Tel Hashomer</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <lastchanged_date>February 12, 2014</lastchanged_date>
  <firstreceived_date>April 9, 2010</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Obsessive Compulsive Disorder</keyword>
  <keyword>Agomelatine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Compulsive Personality Disorder</mesh_term>
    <mesh_term>Obsessive-Compulsive Disorder</mesh_term>
    <mesh_term>Compulsive Behavior</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>S 20098</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
